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Chronic somatic conditions, such as psoriasis, arthritis 
psoriatica and rheumatoid arthritis, have a large im-
pact on patients’ lives. Tailored therapist-guided inter-
net-based cognitive-behavioural therapy (ICBT) has 
been shown to be effective in improving physical and 
psychological well-being in these patients. Two cases 
are presented here, in order to provide an in-depth il-
lustration of the course and content of this novel treat-
ment and to investigate the therapeutic alliance in an 
online treatment. After face-to-face intakes, both pa-
tients received therapist-guided ICBT tailored to their 
specific problems and treatment goals. The treatment 
resulted in improved physical and psychological well-
being and these clinically significant improvements 
were maintained at 6-month follow-up. In addition, 
the therapeutic relationship was evaluated positively 
by both patients and increased further during treat-
ment, indicating an adequate therapeutic working alli-
ance in this online treatment. These case reports show 
that tailored ICBT may contribute to improved care for 
patients with chronic somatic conditions. 
Key words: internet-based intervention; e-health; psoriasis; 
rheumatoid arthritis; cognitive-behavioural therapy; persona-
lized medicine; tailored treatment.
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Chronic somatic conditions, including chronic skin and pain conditions, such as psoriasis (PS), arthritis 
psoriatica (PsA) and rheumatoid arthritis (RA), have a 
large impact on patients and society at large as a con-
sequence of their significant physical and psychosocial 
impact. Patients with these conditions are confronted 
with several physical complaints, including pain, fatigue, 
and itch, as well as psychological complaints, such as 
anxiety and depression, and experience limitations in 
their daily life functioning (1–4). PS, PsA and RA are 
all auto-immune conditions that share specific characte-
ristics with regard to skin problems and pain symptoms. 
PsA and RA cause inflammatory arthritis in the joints, 
leading to pain, stiffness, chronic fatigue, limitations in 
daily life functioning, and a diminished health-related 
quality of life (HRQoL) (5, 6). Fatigue has been identified 
as a key symptom in patients with PsA and RA and was 
added to the core outcome set for future studies, high-
lighting its importance (7–9). Both PS and PsA lead to 
skin lesions characterized by red plaques covered with 
scales. Although there might be some differences with 
regard to the specific pathophysiological mechanisms, 
the experienced symptoms and burden of illness is found 
to be comparable in these patient groups (5, 10–12). 
With regard to psychological functioning, approximately 
30–40% of the patients with chronic skin and pain condi-
tions have elevated distress levels and can be considered 
at risk for long-term psychological adjustment problems 
(13–16). Therefore, a multidisciplinary approach to the 
treatment of these patients is vital. Psychological treat-
ments, such as cognitive behavioural therapy (CBT), 
have been shown to be effective as an adjunct to regular 
medical treatments to improve physical and psycholo-
gical wellbeing for patients with chronic skin and pain 
conditions (17–19). In addition, several studies underline 
the relevance of individually-tailored CBT interventions 
that take patient-specific risk and resilience factors into 
account to further improve treatment adherence and 
effectiveness and decrease attrition rates (20–22). How-
ever, as the lack of specialized therapists and the time 
and travel burden for patients limit the implementation of 
tailored CBT, offering these interventions online might 
present important advantages (23). Research shows 
favourable effects of internet-based CBT (ICBT) for 
chronic somatic conditions (24–26). For example, one 
randomized, controlled trial (RCT) showed that unguided 
ICBT can improve quality of life and levels of anxiety in 
patients with PS, but was limited by high drop-out rates 
(27). Guided ICBT has been associated with lower drop-
out rates and generally higher effectiveness than ICBT 
without therapist support (28–32). Therapist-guided 
ICBT has been shown to be effective for improving 
psychological outcomes (e.g. anxiety, depression and 
distress), disease-specific physical outcomes (e.g. pain, 
fatigue, disability) and disease-related impact outcomes 
(e.g. quality of life) (24, 26). These results are similar to 
those for traditional face-to-face approaches. 
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The therapeutic relationship has been shown to be 
an important factor in predicting treatment outcome in 
face-to-face treatments (33). Also in online treatments, 
the quality of the patient-therapist relationship might 
be related to treatment satisfaction and patient-reported 
improvements (34, 35). Preliminary evidence suggests 
that the therapeutic relationship in internet-based treat-
ments is comparable to that of face-to-face treatments 
(34, 36–38). However, little is known about which factors 
contribute to a successful therapeutic relationship over 
the internet (34). An internet-based treatment may pose a 
challenge for developing a good therapeutic relationship; 
for example, due to the absence of any non-verbal cues. 
On the other hand, patients report specific advantages 
of internet-based treatment that may contribute to an ef-
fective therapeutic alliance, for example the anonymity 
that makes it easier to share personal problems (39). 
The efficacy of a tailored ICBT approach for patients 
with chronic somatic conditions with a psychological 
risk profile was studied in 2 randomized, controlled trials 
(RCTs) for patients with PS (40) and patients with RA (41). 
The current paper describes 2 cases with different di-
seases in order to illustrate this psychological approach, 
which can be used for a variety of problems reported 
by patients with various chronic somatic conditions, 
including chronic skin and pain conditions, such as PS, 
PsA and RA. Therefore, the selected cases experience 
problems that are representative of these conditions, 
including itch–scratch problems, chronic fatigue, phy-
sical limitations, and negative mood. The value of case 
reports is increasingly being recognized in addition to 
RCTs, as this design incorporates unique features, such 
as an in-depth description of the course and content of 
the intervention and the exploration of factors contribu-
ting to possible treatment effectiveness (42). The aim 
of the present article is therefore to provide an in-depth 
illustration of the course and content of the tailored 
therapist-guided ICBT, through 2 case reports differing 
in symptomatology and treatment goals, including 
challenges and obstacles that might be encountered. In 
addition, the development of the therapeutic alliance in 
the online treatment is investigated. 
METHODS
Procedure 
For the 2 RCTs from which the cases reported here were selected, 
inclusion criteria were a diagnosis of PS or RA, age ≥ 18 years, 
and a psychological risk profile (score ≥ 5 for anxiety and/or ≥ 21 
for negative mood measured by the Impact of Rheumatic Diseases 
on General Health and Lifestyle (IRGL; 43, 44) or the Impact of 
Chronic Skin Disease on Daily Life (ISDL; 45). Exclusion criteria 
were: (i) pregnancy, (ii) insufficient understanding of the Dutch 
language, (iii) severe physical or psychiatric comorbidity, (iv) 
current treatment by a cognitive behavioural therapist, and (v) no 
access to a computer and internet. After a screening procedure and 
written informed consent, patients were randomized to the control 
group, who received standard medical care, or the intervention 
group, who received additional ICBT (for a full description of 
both trials, see http://www.trialregister.nl/trialreg/admin/ rctsearch.
asp trial no. NTR2100 and NTR2436). For these case reports, 2 
patients were selected from the RCTs who were representative 
for the ICBT treatment with regard to their reported problems, 
treatment goals and the applied cognitive-behavioural techniques. 
Assessments
Assessments were made with validated instruments before treat-
ment, post-treatment and at 6-month follow-up (FU) (for compara-
bility reasons the 3-, 9- and 12-month follow-up assessments of the 
RA trial were not included). Tables SI1 and SII1 give an overview 
of the outcome measures used for both the PS and the RA patient.
Physical functioning. Fatigue was measured with the 8-item fatigue 
subscale of the Checklist Individual Strength (CIS; 46, 47) in both 
patients. Itch was assessed in the patient with PS with the 4-item 
itch subscale of the ISDL. Pain was assessed in the patient with RA 
with the IRGL pain scale. Higher scores reflect more symptoms 
of fatigue, itch and pain. 
Psychological functioning. For both cases, depressive symptoms 
were assessed with the Beck Depression Inventory (BDI; 48) 
and negative mood and anxiety by their respective scales of the 
IRGL/ISDL, with higher scores reflecting worse psychological 
functioning. 
Impact on daily life. Role limitations due to physical health pro-
blems and emotional problems of the RAND-36 Health Status 
Inventory were assessed, with higher scores reflecting less impact 
(49, 50). For the patient with RA, the self-care and mobility scales 
of the IRGL were also administered, with higher scores indicating 
better functioning. 
Cognitive-behavioural factors. Cognitive-behavioural factors were 
assessed, including illness cognitions of helplessness and accep-
tance (Illness Cognitions Questionnaire, ICQ; 51), social factors 
including perceived social support (IRGL/IHDL) and stigmatiza-
tion (ISDL; only for the patient with PS), and worrying (Penn 
State Worry Questionnaire, PSWQ; 52). In addition, for the patient 
with PS, scratching behaviour was assessed with the subscales 
conscious scratching and automatic scratching of the ISDL. For 
the patient with RA, passive (resting, retreating, worrying) and 
active (pain transformation, distraction, reducing demands) pain 
coping was assessed with the Pain Coping Inventory (PCI; 53). 
Disease-related variables. Disease activity was assessed in the 
patient with PS with the Psoriasis Area and Severity Index (PASI; 
54), with higher scores signifying greater disease severity. The 
Self-Administered Psoriasis Area and Severity Index (SAPASI; 
55) was also used to measure self-assessed disease severity, with 
higher scores indicating more severe self-perceived psoriasis. 
For the patient with RA, disease activity was assessed using the 
self-report measure Rheumatoid Arthritis Disease Activity Index 
(RADAI; 56), with higher scores reflecting higher self-reported 
disease activity. Medical treatment compliance was assessed with 
a questionnaire asking how often patients adhered to medical 
treatment prescriptions/recommendations with regard to several 
aspects of the medical care (57). Each question could be answered 
on a 5-point Likert scale, ranging from less than once a week to 7 
days a week, or could be answered as “not applicable”. Total sco-
res were constructed by calculating the mean of applicable items, 
with higher scores indicating greater self-reported compliance. 
Therapeutic relationship. To assess the quality of the therapeutic 
relationship, the Working Alliance Inventory short-form (WAI-S; 
58, 59) was administered after the 2 face-to-face intakes and at the 
end of treatment. A higher score indicates a more positive thera-
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2803
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peutic alliance. In addition, the newly developed Internet-Specific 
Therapeutic Relationship Questionnaire (ITRQ; 35) was used, 
with higher scores reflecting a more positive therapeutic alliance. 
Patient evaluation. Finally, an evaluation questionnaire was ad-
ministered post-treatment to assess patients’ satisfaction with the 
ICBT intervention and their evaluation of the user-friendliness of 
the website on a 10-point scale. In addition, they were asked to 
evaluate on a 6-point scale whether the contact with the therapist 
was motivating and useful. 
Data analysis
Post-treatment and 6 months’ follow-up scores of the 2 cases 
were compared with their baseline scores (pre-assessment) and to 
scores of normative samples (healthy controls or normative group 
of patients with PS or RA for outcomes that can only be assessed 
in patient populations). Clinically significant improvement was 
defined in 2 ways: (i) showing a change from baseline of more 
than 0.5 standard deviation (SD), using the SD of the normative 
sample (60), and (ii) showing an improvement from baseline of 
at least 30%, as recommended by the IMPPACT guidelines for 
clinical trials (61). 
Internet-based cognitive-behavioural therapy
Prior to ICBT, patients were invited to attend 1 or 2 face-to-face 
intake sessions with the therapist, during which the treatment 
goals were mutually determined. Thereafter, patients started with 
the online intervention. The ICBT began with an introductory 
module, during which the specific treatment targets within one 
or 2 of the 5 treatment modules (pain, itch, fatigue and physical 
limitations, negative mood, and social relationships) were selected 
based on the pre-treatment assessment and the intake interviews. 
Next, within the chosen treatment modules a flexible protocol was 
used, consisting of various assignments, such as self-monitoring 
exercises and psycho-educational texts. The ICBT was designed as 
a tailored, personalized treatment. The therapist selected assignme-
nts and online texts that were most suitable to patients’ individual 
problems, treatment goals, and perpetuating cognitive-behavioural 
factors, and gave individualized feedback on assignments approx-
imately once a week. In addition, patients could send messages to 
the therapist at their own discretion. The treatment concluded with 
relapse prevention and long-term goals (see Fig. 1 for a schematic 
overview of the treatment). The treatment protocol was based on 
techniques from face-to-face standardized treatment protocols for 
various chronic somatic conditions (20, 22, 62, 63).
CASE REPORTS
Case 1 
Case description. A 64-year-old man, married, retired, 
had had progressive skin complaints since he was 36 
years old, diagnosed as PS. PS is a chronic inflam-
matory auto-immune skin condition that causes red 
plaques covered with white scales that are frequently 
accompanied by itch, fatigue and, occasionally, pain. 
The skin condition had a large impact on his daily life. 
He reported having high levels of itch and, in response, 
he scratched a lot. He also scratched as an automatic 
behaviour unrelated to itch, e.g. as a habit and in stressful 
situations. This scratching behaviour led to skin damage 
and an aggravated skin condition, which resulted in 
even more itch. Thus, a vicious cycle of itch-scratching 
problems developed (64, 65). He also reported feeling 
depressed and anxious as a result of his psoriasis. He 
felt helpless in dealing with his skin complaints due to 
numerous unsuccessful coping efforts. In addition, due 
to shame with regard to his scratching behaviour, he 
avoided social activities, which further aggravated his 
negative mood. He also found it difficult to accept the 
unpredictable nature of his condition. This led to a high 
level of experienced stress and he reported that this, in 
turn, negatively affected the psoriasis. 
The pre-assessment supported a high level of itch, 
scratching behaviour, negative mood and feelings of 
helplessness compared with a norm group (Table SI1). 
Based on this assessment and according to the face-to-
face intakes, in which the treatment goals and specific 
treatment modules tailored to these goals were mutually 
determined by the patient and therapist, the ICBT con-
sisted of the treatment modules itch and negative mood 
in achieving the treatment goals of diminishing itch-
scratching problems and improving mood. The course of 
the treatment will be described below in order to illustrate 
different treatment methods of the ICBT in more detail. 
Treatment. The ICBT consisted of the introductory mo-
dule, module itch, module negative mood, and the clo-
sing module. The patient logged in 47 times, completed 
37 assignments (95% of the total given assignments), 
received 13 messages from the therapist, and sent 11 
messages within a period of 5 months (1-week intro-
duction module, 8-week itch module, 9-week negative 
mood module, 2-week closing module). In addition, one 
phone call was made by the therapist during the online 
treatment to clarify a given assignment. 
Introductory module. In the introductory module, treat-
ment goals were set. For this patient, the most important 
treatment goals were decreasing itch-scratching problems 
and improving mood. Because the itch and scratching 
problems were of central importance and also influenced 
his mood, the itch module was chosen as a starting point.
Itch module. Several psycho-educational texts and 
exercises were used to diminish the itch-scratching pro-
Face-to-face intakes
Introductory module:
Goal setting and choice of
treatment modules
Fatigue and
physical limitations
Pain           Itch Negative
mood
Social
relationships
Closing module:
Relapse prevention and
long-term goals
Fig. 1. Overview of the therapist-guided, tailored internet-based 
cognitive-behavioural treatment.
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blems. First, he started to keep a self-monitoring diary 
on which, every day at a set time, he recorded the level 
of itch and the number of times he scratched himself, in 
addition to recurrent risk situations for itch and scrat-
ching. Next, psycho-education about the vicious cycle 
of itch-scratching problems was provided and exercises 
to decrease scratching, including habit reversal in which 
patients learn to replace scratching with incompatible 
behaviour. He indicated that the self-monitoring exer-
cises made him more aware of his scratching behaviour 
and that the incompatible behaviour was helping him 
to control his scratching better. Attention was also paid 
to coping techniques to deal with triggering factors of 
itch and scratching. For example, since water was a 
triggering factor for the patient’s itch, he took shorter 
showers. Because the patient felt very stressed when he 
experienced itch, psycho-education was provided about 
the relationship between stress, itch, and scratching, in 
addition to exercises about stress-relieving strategies, 
such as itch-relieving thoughts and visualizations. For 
example, he began using self-thoughts such as “I can 
tolerate the itch” and “The itch will go away eventu-
ally”, which helped him stay more relaxed when the 
itch increased. 
Negative mood module. Given the high levels of stress, 
the patient experienced in his daily life and the possible 
negative effect on his psoriasis, in the negative mood 
module attention was paid to stress management. Several 
methods to deal with stress were offered, e.g. relaxation 
exercises, distraction, problem-solving, and reappraising 
the situation. He had access within the website to various 
audio-tracks that contain recorded relaxation exercises 
(including progressive muscle relaxation, cued relaxa-
tion, and visualization exercises). He completed one 
exercise a day and reported that this had a positive ef-
fect on his perceived stress. He was also encouraged to 
regularly apply relaxing and distracting activities in his 
daily life, e.g. reading, gardening, cycling, and walking. 
In addition, cognitive restructuring techniques were 
applied. The patient learned to challenge dysfunctional 
cognitions, such as “It is pointless” and “Nothing is 
helping”, and transform them into more helpful thoughts 
such as “I can manage”. After several weeks, he indica-
ted that he was barely stressed anymore, his depressive 
feelings were greatly diminished, and he withdrew less 
from social activities. 
Closing module: relapse prevention and long-term goals. 
Given the progress with regard to the treatment goals, it 
was mutually decided to end the treatment. The closing 
module dealt with relapse prevention and further im-
provement of the attained goals. The patient stated that 
he achieved all of his goals. A relapse prevention plan 
was formulated by the patient, including detecting early 
signs of relapse (e.g. tension) and preventive actions (e.g. 
relaxation exercises). 
Case 2
Case description. A 26-year-old woman, living together 
with a steady partner, had started having pain in her 
wrist and knee one year previously. A few months later, 
she was diagnosed with RA by her rheumatologist. RA 
is characterized by inflammation in the joints that fre-
quently leads to functional disability, pain, and fatigue. 
The patient worked as a dental assistant for 32 h a week. 
Pain and fatigue were her most prominent complaints, 
which limited her daily activities. She tried to ignore 
her complaints, rested very little between activities and 
would spend only a small amount of her time on pleasant 
activities. Whenever she had relatively few complaints, 
she was very active to make up for earlier periods of 
experienced loss of productivity. However, these peaks 
of activity were generally followed by days of exhaus-
tion. In the long run, this over-exertion pattern had led 
to an increase in complaints and exhaustion. She also 
worried a lot about how to deal with her complaints 
and limitations. Her worrying and the diminishment of 
pleasant activities had a negative impact on her mood. 
The pre-assessment supported the over-exertion pat-
tern and showed very high levels of pain and fatigue, 
depressive symptoms, high levels of worrying, and low 
acceptance compared with a norm group (see Table 
SII1). Based on this assessment and according the face-
to-face intakes in which the treatment goals and specific 
treatment modules tailored to these goals were mutually 
determined by the patient and the therapist, the ICBT of 
the patient consisted of the treatment modules fatigue 
and physical limitations and negative mood in achieving 
the treatments goals of less fatigue and improved mood.
Treatment. The ICBT for the patient consisted of the 
introductory module, fatigue and physical limitations 
module, negative mood module and the closing module. 
In total, the patient logged in 45 times, completed 31 as-
signments (82% of the given assignments), received 20 
messages from the therapist and sent 22 messages within 
a period of approximately 6 months (1-week introduction 
module, 10-week fatigue and physical limitations module, 
7-week negative mood module, 3-week closing module).
Introductory module. In this module, treatment goals 
were set. For the patient, the most important treatment 
goals were improving her level of fatigue and, to a lesser 
extent, pain (e.g. better alternation of rest and activity, 
becoming more aware of limits) and improving her mood 
(e.g. less worrying, less depressive mood).
Fatigue and physical limitations module. By means of 
self-monitoring of daily activities and levels of fatigue, 
pain, and mood, it was revealed to the patient that she 
went on with activities for a long time without breaks, 
which increased her complaints. In addition, a registra-
tion of her daily activities and the amount of energy that 
each activity costs revealed that she overexerted herself 
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on most days. Psycho-education with reading texts was 
given regarding the importance of balancing activity 
and relaxation to prevent symptoms from aggravating, 
in addition to exercises aimed at achieving this balance, 
e.g. structured planning of daily activities and activity 
pacing (alternating activity and relaxation, spreading out 
intense activities), balancing enjoyable, important, and 
necessary activities. The patient indicated that she pro-
fited greatly from planning her activities more carefully, 
while focusing more on enjoyable activities. Since she 
reported waking up very tired in the morning, attention 
was paid to sleep hygiene. By keeping a sleep schedule 
for a few days, she learned that being too busy before 
going to bed caused her poor sleep quality. She started 
addressing this problem by implementing more relaxing 
activities, such as reading or taking a bath before she 
went to bed, which diminished her fatigue complaints 
in the morning. 
Negative mood module. In the negative mood module, 
psycho-education about coping with worrying and 
exercises about stress-management strategies was of-
fered. The patient regularly practiced various coping 
techniques (e.g. planning 15 min a day for worrying, 
distraction, problem-solving, and challenging dysfun-
ctional thoughts). Attention was also paid to increasing 
the amount of pleasant activities and the patient was 
asked to schedule at least one enjoyable activity per day. 
She was actively involved in this exercise and felt that 
it improved her negative mood symptoms. In addition, 
attention was paid to coping with dysfunctional thoughts 
by using techniques such as cognitive restructuring, 
problem-solving and distraction. Finally, relaxation ex-
ercises were provided to help her diminish her worrying 
further and to create more moments of relaxation in her 
daily life. In a telephone call, she indicated that, due to a 
new job, she had no time to practice these exercises at the 
moment. Therefore, she was offered an audio-CD with 
the exercises, so she could practice these in the future. 
Closing module: relapse prevention and long-term 
goals. Given the progress with regard to the treatment 
goals, it was decided to conclude the treatment. In the 
closing module, attention was paid to relapse prevention 
and future goals. The patient reported having reached 
all of her treatment goals to a large extent. In a relapse 
prevention plan, she formulated early signs of relapses 
(e.g. increase fatigue) and preventive actions (e.g. adjust 
daily planning, include more time for relaxation and 
pleasant activities). 
RESULTS
Patient evaluation
After completing the interventions, both case 1 and case 
2 reported that the intervention had been very helpful 
and rated the overall intervention as a 9 on a 10-point 
scale. Case 1 reported that he could cope better with 
the itch, scratched less and had greatly diminished his 
feelings of helplessness and depression. Case 2 repor-
ted to be better able to respect her boundaries and stop 
in time. Her fatigue and pain complaints were greatly 
diminished, she worried less and her mood was impro-
ved. With regard to the internet-delivered aspect of the 
treatment, both patients evaluated the user friendliness 
of the website positively (case 1: 9; case 2: 10; scale 
1–10). Furthermore, specific items of the ITRQ showed 
that they both reported as important advantages of online 
treatment that they had the time to think about the mes-
sage to the therapist (case 1: 10; case 2: 10; scale 1–10), 
it was easier to share personal problems (case 1: 8; case 
2: 10; scale 1–10), and that writing down their feelings 
and thoughts helped to clarify them (case 1: 10; case 2: 
10; scale 1–10). Case 1 also reported as advantage the 
ease of following a treatment at home and not having to 
travel to the hospital (case 1: 8; scale 1–10). Furthermore, 
they both stated that the face-to-face intakes were a very 
important aspect of the treatment (10, scale 1–10). In 
addition, they both indicated that the contact with the 
therapist was very motivating (6, scale 0–6) and useful 
(6, scale 0–6). Finally, they both indicated a preference 
for internet-based treatment over other forms of treatment 
(phone-based, face-to-face) for future treatment. 
Pre-post and follow-up improvements
For case 1, with regard to physical functioning, impro-
vements were found for itch and fatigue at post- and 
follow-up assessments. Also, improvements were found 
for psychological functioning, including negative mood 
and depression. The level of anxiety was diminished at 
post-assessment, but the score at the FU showed a slight 
increase. The impact on daily life was at the maximal 
level at pre-treatment and remained stable during the 
treatment and at FU. In contrast, the clinician-assessed 
disease severity worsened slightly between pre- and FU-
assessment, suggesting the possible use of more adequate 
cognitive-behavioural strategies to cope with the symp-
toms and consequences of the disease. Indeed, the level 
of helplessness and scratching behaviour decreased. No 
large differences were found with regard to the level of 
worrying, which was within the range of healthy controls 
at all assessment. Also, illness cognitions of acceptance 
remained overall stable. The level of social support was 
already high at pre-treatment and the experienced stigma-
tization low, and these outcomes remained stable. Also, 
case 1 had the maximal score for treatment compliance at 
pre-, post- and FU-assessment. With regard to the clinical 
relevance of these results, case 1 showed improvements 
of > 0.5 SD for all outcomes at post-assessment and FU, 
with the exception of anxiety and acceptance at FU. In 
addition, the improvement from baseline was at least 30% 
for most outcomes at post-assessment, with the excep-
tion of itch, acceptance, worrying and the self-assessed 
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
S. Spillekom-van Koulil et al.230
www.medicaljournals.se/acta
disease severity, and for most outcomes at FU, with the 
exception of itch, anxiety, acceptance, worrying and 
clinician-assessed disease severity (Table SI1). 
For case 2, large improvements were found for the 
physical outcomes of pain and fatigue (at FU within range 
of healthy controls). In addition, the psychological out-
comes showed relatively large improvements, including 
depression, negative mood, and anxiety. With regard to 
the impact on daily life, self-care and emotional role fun-
ctioning were at the maximal level at pre-treatment and 
remained stable, and relatively large improvements were 
found with regard to level of mobility and physical role 
functioning. However, the disease severity of case 2 also 
decreased, which makes it difficult to determine whether 
these improvements can be attributed to the psychological 
treatment alone. Nevertheless, the cognitive-behavioural 
factors at post-treatment indicate that she applied more 
adaptive pain-coping techniques, such as distracting and 
reducing demands, and she also rested more. No changes 
were found with regard to the pain-coping strategies of 
transforming pain and retreating. At follow-up, case 2 
stated she could not complete the pain-coping measures 
because she did not have pain anymore. In addition, 
feelings of helplessness diminished, acceptance impro-
ved and her level of worrying decreased. Social support 
was already at the maximal score at pre-treatment and 
remained stable. Also, the treatment compliance was at 
a maximal score at all assessment points. With regard 
to the clinical relevance of these results, case 2 showed 
improvements of > 0.5 SD for most outcomes at post-
assessment, with the exception of social support and 
the pain-coping strategies of retreating, worrying, and 
transforming pain, and on all outcomes at FU. In addi-
tion, the improvement from baseline was at least 30% for 
most outcomes at post-assessment, with the exception of 
pain, anxiety, and the pain-coping strategies of resting, 
retreating, worrying and transforming pain, and for all 
outcomes at FU (see Table SII1). 
Therapeutic alliance
The results of the WAI (Table I) showed that the agree-
ment on treatment tasks and treatment goals was already 
high after the face-to-face intakes and improved even 
further during treatment. Also, the emotional bond was 
established at the maximal level after the face-to-face 
intakes and remained stable during the online treatment 
without direct face-to-face contact. In addition, results 
for the internet-specific aspects of the therapeutic alliance 
assessed with the ITRQ showed a similar pattern. More 
specifically, both patients reported that it was clear from 
the assignments and messages from the therapist that 
she had thought thoroughly about what is important for 
them at the moment, that the therapist had paid sufficient 
attention to their problems and treatment goals, and took 
their personal problems seriously. 
DISCUSSION
ICBT has been shown to be effective for patients with 
several chronic somatic conditions. These 2 case re-
ports provide an in-depth illustration of the course and 
content of a therapist-guided tailored ICBT approach 
for patients with chronic somatic conditions, such as 
PS, PsA and RA, and a psychological risk profile. In 
addition, the development of a therapeutic alliance in 
an internet-delivered treatment was investigated. For 
both cases the tailored ICBT approach proved effective. 
Post-treatment clinically meaningful improvements were 
found with regard to their physical and psychological 
wellbeing, which remained stable or further improved 
6 months after treatment, suggesting that both patients 
continued to benefit from the treatment. Also, the cog-
nitive-behavioural factors, including illness cognitions, 
social support, worrying and coping strategies, showed 
clinically relevant improvements at post-treatment and 
follow-up. Furthermore, a successful therapeutic alliance 
was established for both patients after the face-to-face 
intakes, which further improved during treatment. 
Over the last few years, researchers and clinicians have 
increasingly focused on the importance of tailoring treat-
ment to patients’ needs in order to improve treatment ef-
ficacy and increase adherence. As psychological distress 
can influence disease course, adherence and treatment 
success, it is clinically relevant to select patients with 
a psychological risk profile (66, 67). Therefore, in our 
RCTs, only patients with a heightened distress level at 
risk for long-term adjustment problems were selected for 
the ICBT. In addition, since incorporating patient prefe-
rences may increase treatment satisfaction and lower att-
rition rates, the specific treatment modules were matched 
to the outcomes from which the patients suffered most 
(28). Finally, based on the cognitive-behavioural factors 
that were assumed to perpetuate the complaints, specific 
assignments were chosen within the treatment modules. 
For example, for both patients the negative mood module 
Table I. Mean scores of cases 1 and 2 at pre- and post-assessment 
on the therapeutic relationship outcomes including the range of 
measures used
Outcome measures Pre Post Range
Therapeutic relationship (WAI)
Case 1
Agreement treatment tasks 4.25 4.75 1–5
Agreement treatment goals 4.50 4.75 1–5
Emotional bond 5.00 5.00 1–5
Case 2
Agreement treatment tasks 4.75 5.00 1–5
Agreement treatment goals 4.50 4.75 1–5
Emotional bond 5.00 5.00 1–5
Internet-Specific Therapeutic Relationship Questionnaire (ITRQ)
Case 1
Time and attention 10.00 10.00 1–10
Reflection and comfort 9.00 9.00 1–10
Case 2
Time and attention 9.75 10.00 1–10
Reflection and comfort 7.75 8.75 1–10
WAI: Working Alliance Inventory short-form.
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was relevant, but for case 1 the focus within the module 
was on diminishing feelings of helplessness and expe-
rienced stress, and for case 2 on diminishing her worrying 
and increasing pleasant activities. Although the HRQoL 
is equally diminished in chronic somatic conditions, such 
as PS, PsA and RA, it has been argued that different 
aspects of the disease might contribute to this lowered 
HRQoL (10). For example, in PsA and RA it has been 
suggested that the physical symptoms and fatigue impact 
the patient most, while PS might have a greater impact on 
mental health (including social functioning) (6, 68). Case 
2, indeed, experienced high levels of fatigue and pain 
that limited her daily life functioning. Case 1, however, 
did not experience limitations in his social functioning 
and was also mostly impaired in his physical functioning 
due to the high levels of experienced itch. Nevertheless, 
the specific factors contributing to diminished HRQoL 
in a specific patient also needs to be taken into account 
when tailoring treatment to specific problems.
The results of the therapeutic alliance support earlier 
findings on the possibility of successfully forming and 
maintaining a therapeutic relationship in internet-delive-
red treatments. Since the working alliance at the begin-
ning of treatment can be predictive of treatment outcome, 
as was also shown in a psoriasis RCT (40), this is an 
important result. There are various conceptualizations 
of the therapeutic alliance, but most share 3 themes: (i) 
collaborative nature, (ii) affective bond between patient 
and therapist, and (iii) ability to agree on treatment goals 
and tasks (33). Specific aspects of this ICBT treatment 
focused on these themes, which might have contributed 
to the development of this adequate therapeutic rela-
tionship, including the face-to-face intakes to establish 
the emotional bond, treatment goals that were mutually 
determined, the personalized treatment plan, assignments 
and messages, and regular contact with the possibility 
for the patients to send messages to the therapist at their 
own discretion. These aspects were highly valued by both 
patients. Further research is needed to investigate the 
development of a therapeutic alliance in internet-based 
treatments in more detail, for example by including other 
treatment modalities, such as video conferencing and 
chatting, where the verbal cues are not missing. 
Several limitations of this study need to be taken into 
account. The results of the case reports do not prove the 
efficacy of this tailored treatment, which has been eva-
luated in RCTs (40, 41). In addition, it is unclear whether 
these results can be generalized to a broader population, 
including patients with physical and/or psychiatric co-
morbidity. ICBT might only be suitable for patients with 
chronic somatic conditions with moderate adjustment 
problems, while a face-to-face treatment is needed for 
those patients with severe adjustment problems or mul-
timorbidity. Due to the tailored approach and generic 
treatment modules, this ICBT could also be useful for 
patients with other chronic somatic conditions, inclu-
ding patients with chronic skin conditions, chronic pain 
conditions, diabetes, and cardiovascular conditions, al-
though future research is needed to establish this further. 
Furthermore, future research should aim at delineating 
the specific mediating and moderating factors of this 
tailored ICBT. In addition, more research is needed with 
regard to ways of establishing the clinical relevance of 
treatment effects.
In conclusion, ICBT offers several advantages, such as 
the absence of travelling time, and costs and flexibility 
in choosing the time of treatment. These case reports 
demonstrate that a therapist-guided, individually tailored 
ICBT treatment is feasible and can result in meaningful 
changes for patients with chronic somatic conditions and 
a psychological risk profile.
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